Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease

Journal of Medical Virology

Volumn 68, Issue 3, 2002, Pages 370-377

  Meij, Pauline ^a   Vervoort, Marcel B H J ^a   Bloemena, Elisabeth ^a   Schouten, Tabitha E ^a   Schwartz, Cindy ^b   Grufferman, Seymour ^c   Ambinder, Richard F ^b   Middeldorp, Jaap M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

EBV; Immunity; Immunological selection; Oncogenesis; Serology

Indexed keywords

LATENT MEMBRANE PROTEIN 1; MEMBRANE PROTEIN; VIRUS CAPSID ANTIGEN;

ADOLESCENT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CHILD; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; T LYMPHOCYTE ACTIVATION; VIRUS DETECTION; VIRUS EXPRESSION;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; IMMUNOBLOTTING; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 0036836520     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10213     Document Type: Article

References (34)

1. Ambinder RF. 2000. Gammaherpesviruses and "hit-and-run" oncogenesis. Am J Pathol 156:1-3.
2. Ambinder RF, Mann RB. 1994. Detection and characterization of Epstein-Barr virus in clinical specimens. Am J Pathol 145:239-252.
3. Axdorph U, Porwit-MacDonald A, Sjoberg G, Ekman M, Wang W, Biberfeld P, Bjorkholm M. 1999. Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum factors and blood lymphocyte function. Br J Cancer 81:1182-1187.
4. Brooks LA, Lear AL, Young LS, Rickinson AB. 1993. Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. J Virol 67:3182-3190.
5. Chen HF, Kevan-Jah S, Suentzenich KO, Grasser FA, Mueller-Lantzsch N. 1992. Expression of the Epstein-Barr virus latent membrane protein (LMP) in insect cells and detection of antibodies in human sera against this protein. Virology 190:106-115.
6. Devergne O, Hatzivassiliou E, Izumi KM, Kage KM, Kleijnen MF, Kieff E, Mosialos G. 1996. Association of TRAF1, TRAF2 and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-κB activation. Mol Cell Biol 16:7098-7108.
7. Dukers DF, Meij P, Vervoort MBHJ, Vos W, Scheper RJ, Meijer CJLM, Bloemena E, Middeldorp JM. 2000. Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. J Immunol 165:663-670.
8. Enblad F, Sandvej K, Lennette E, Sundstrom S, Klein G, Bengt G, Pallesen G. 1997. Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease. Int J Cancer 72:394-397.
9. Floettmann JE, Eliopoulos AF, Jones M, Young LS, Rowe M. 1998. Epstein-Barr virus latent membrane protein- 1 (LMP1) signalling is distinct form CD40 and involves physical cooperation of its two C-terminal functional regions. Oncogene 17:2383-2392.
10. Glaser SL, Lin RJ, Stewart SL, Ambinder RF, Jarett RF, Brousset P, Pallesen G, Gulley ML, Khan G, O'Grady J, Hummel M, Preciado MV, Knecht H, Chan JK, Claviez A. 1997. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 70:375-382.
11. Herbst H, Dallenbach R, Hummel M, Niedobitek G, Pileri S, Mueller-Lantzsch N, Stein H. 1991. Epstein-Barr latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc NatlAcad Sci USA 88:4766-4770.
12. Hjalgrim H, Askling J, Sörensen P, Madsen M, Rosdahl N, Storm HH, Hamilton-Dutoit S, Stener Eriksen L, Frisch M, Ekbom A, Melbye M. 2000. Risk of Hodgkin's disease and other cancers after infectious mononucleosis. J Natl Cancer Inst 92:1522-1528.
13. Jiwa NM, Oudejans JJ, Dukers DF, Vos W, Horstman A, van der Valk P, Middeldorp JM, Walboomers JMM, Meijer CJLM. 1995. Immunohistochemical demonstration of different latent membrane protein-1 epitopes of Epstein-Barr virus in lymphoproliferative diseases. J Clin Pathol 48:438-442.
14. Khanna R, Burrows SR, Nichills J, Poulsen LM. 1998. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype restricted immune recognition of EBV-infected cellsby LMP1-specific cytotoxic T lymphocytes. Eur J Immunol 28:451-458.
15. Khanna R, Moss DJ, Burrows SR. 1999. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 170: 49-64.
16. Kieff E. 1996. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott-Raven. p 2343-2396.
17. + T-helper 1 responses. J Virol 75:8649-8659.
18. Meij P, Vervoort MBHJ, Aarbiou J, van Dissel P, Brink A, Bloemena E, Meijer CJLM, Middeldorp JM. 1999. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases. J Infect Dis 179:1108-1115.
19. Meij P, Vervoort MBHJ, Meijer CJLM, Bloemena E, Middeldorp JM. 2000. Production monitoring and purification of EBV encoded latent membrane protein 1 expressed and secreted by recombinant baculovirus infected insect cells. J Virol Methods 90:193-204.
20. Meij P, Leen A, Rickinson AB, Verkoeijen S, Vervoort MB, Bloemena E, Middeldorp JM. 2002. Identification and prevalence of CD8(t) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int J Cancer 99:93-99.
21. Middeldorp J.M. US patent no. 5843405.
22. Middeldorp JM, Herbrink P. 1988. Epstein-Barr virus specific marker molecules for early diagnosis of infectious mononucleosis. J Virol Methods 21:133-146.
23. Modrow S, Wolf H. 1986. Characterization of two related Epstein-Barr virus-encoded membrane proteins that are differentially expressed in Burkitt lymphoma and in vitro-transformed cell lines. Proc Natl Acad Sci USA 83:5703-5707.
24. Mueller N. 1987. Epidemiologic studies assessing the role of Epstein-Barr virus in Hodgkin's disease. Yale J Biol Med 60:321-332.
25. Mueller N, Evans A, Harris NL, Costock GW, Jellum E, Magnus K, Orentreich N, Polk BF, Vogelman J. 1989. Hodgkin's disease and Epstein-Barr virus. Altered antibody patterns before diagnosis. N Engl J Med 320:689-695.
26. Nakagomi H, Dolcetti R, Bejarano MT, Pisa P, Kiessling R, Masucci MG. 1994. The Epstein-Barr virus transformation induces B lymphocytes to produce interleukin 10. Int J Cancer 57:240-244.
27. Niedobitek G, Kremmer E, Herbst L, Whitehead L, Dawson CW, Niedobitek E, von Ostau C, Rooney N, Grasser FA, Young LS. 1997. Immunohistochemical detection of the Epstein-Barr latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood 90:1664-1672.
28. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. 1991. Expression of Epstein-Barr virus latent gene products in tumor cells of Hodgkin's disease. Lancet 337:320-322.
29. Rickinson AB, Kieff E. 1996. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott-Raven. p 2397-2446.
30. Rowe M, Finke J, Szigeti R, Klein G. 1988. Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus. J Gen Virol 69:1217-1228.
31. Uchida J, Teruhito Y, Takaoka-Shichijo Y, Muraoka M, Kulwichit W, Raab-Traub N, Kikutani H. 1999. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 286:300-303.
32. van Grunsven WMJ, NabbeA, Middeldorp JM. 1993. Identification and molecular characterization of two diagnostically relevant marker proteins of the Epstein-Barr virus capsid antigen complex. J Med Virol 40:161-169.
33. van Grunsven WMJ, Spaan WJM, Middeldorp JM. 1994. Localization and diagnostic application of immunodominant domains of the BFRF3-encoded Epstein-Barr virus capsid protein. J Infect Dis 170:13-19.
34. Xu J, Ahmad A, D'Addario M, Knafo L, Jones JF, Prasad U, Dolcetti R, Vaccher E, Menezes J. 2000. Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases. J Immunol 164:2815-2822.